IBDEI03U ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1264,1,4,0)
 ;;=4^C79.52
 ;;^UTILITY(U,$J,358.3,1264,2)
 ;;=^5001351
 ;;^UTILITY(U,$J,358.3,1265,0)
 ;;=C79.71^^3^39^125
 ;;^UTILITY(U,$J,358.3,1265,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1265,1,3,0)
 ;;=3^Secondary malignant neoplasm of right adrenal gland
 ;;^UTILITY(U,$J,358.3,1265,1,4,0)
 ;;=4^C79.71
 ;;^UTILITY(U,$J,358.3,1265,2)
 ;;=^5001356
 ;;^UTILITY(U,$J,358.3,1266,0)
 ;;=C79.72^^3^39^122
 ;;^UTILITY(U,$J,358.3,1266,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1266,1,3,0)
 ;;=3^Secondary malignant neoplasm of left adrenal gland
 ;;^UTILITY(U,$J,358.3,1266,1,4,0)
 ;;=4^C79.72
 ;;^UTILITY(U,$J,358.3,1266,2)
 ;;=^5001357
 ;;^UTILITY(U,$J,358.3,1267,0)
 ;;=C83.50^^3^39^46
 ;;^UTILITY(U,$J,358.3,1267,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1267,1,3,0)
 ;;=3^Lymphoblastic (diffuse) lymphoma, unspecified site
 ;;^UTILITY(U,$J,358.3,1267,1,4,0)
 ;;=4^C83.50
 ;;^UTILITY(U,$J,358.3,1267,2)
 ;;=^5001581
 ;;^UTILITY(U,$J,358.3,1268,0)
 ;;=C83.59^^3^39^47
 ;;^UTILITY(U,$J,358.3,1268,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1268,1,3,0)
 ;;=3^Lymphoblastic lymphoma, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,1268,1,4,0)
 ;;=4^C83.59
 ;;^UTILITY(U,$J,358.3,1268,2)
 ;;=^5001590
 ;;^UTILITY(U,$J,358.3,1269,0)
 ;;=C83.70^^3^39^18
 ;;^UTILITY(U,$J,358.3,1269,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1269,1,3,0)
 ;;=3^Burkitt lymphoma, unspecified site
 ;;^UTILITY(U,$J,358.3,1269,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,1269,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,1270,0)
 ;;=C83.79^^3^39^17
 ;;^UTILITY(U,$J,358.3,1270,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1270,1,3,0)
 ;;=3^Burkitt lymphoma, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,1270,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,1270,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,1271,0)
 ;;=C81.90^^3^39^40
 ;;^UTILITY(U,$J,358.3,1271,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1271,1,3,0)
 ;;=3^Hodgkin lymphoma, unspecified, unspecified site
 ;;^UTILITY(U,$J,358.3,1271,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,1271,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,1272,0)
 ;;=C81.99^^3^39^39
 ;;^UTILITY(U,$J,358.3,1272,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1272,1,3,0)
 ;;=3^Hodgkin lymphoma, unsp, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,1272,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,1272,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,1273,0)
 ;;=C82.90^^3^39^33
 ;;^UTILITY(U,$J,358.3,1273,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1273,1,3,0)
 ;;=3^Follicular lymphoma, unspecified, unspecified site
 ;;^UTILITY(U,$J,358.3,1273,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,1273,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,1274,0)
 ;;=C82.99^^3^39^32
 ;;^UTILITY(U,$J,358.3,1274,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1274,1,3,0)
 ;;=3^Follicular lymphoma, unsp, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,1274,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,1274,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,1275,0)
 ;;=C91.40^^3^39^34
 ;;^UTILITY(U,$J,358.3,1275,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1275,1,3,0)
 ;;=3^Hairy cell leukemia not having achieved remission
 ;;^UTILITY(U,$J,358.3,1275,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,1275,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,1276,0)
 ;;=C90.00^^3^39^88
 ;;^UTILITY(U,$J,358.3,1276,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1276,1,3,0)
 ;;=3^Multiple myeloma not having achieved remission
 ;;^UTILITY(U,$J,358.3,1276,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,1276,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,1277,0)
 ;;=C90.01^^3^39^87
 ;;
 ;;$END ROU IBDEI03U
